<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The <z:e sem="disease" ids="C0002875" disease_type="Disease or Syndrome" abbrv="">beta-thalassemia major</z:e> is a common hereditary hematology disease in southern China </plain></SENT>
<SENT sid="1" pm="."><plain>The combination of blood transfusion and iron chelation is now the reference treatment </plain></SENT>
<SENT sid="2" pm="."><plain>The allogeneic hematopoietic stem cell transplantation is the only curative therapy for <z:e sem="disease" ids="C0002875" disease_type="Disease or Syndrome" abbrv="">beta-thalassemia major</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>In this study the investigators observed and evaluated the effects of umbilical cord blood transplantation (UCBT) for patients with <z:e sem="disease" ids="C0002875" disease_type="Disease or Syndrome" abbrv="">beta-thalassemia major</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Twelve cases of <z:e sem="disease" ids="C0002875" disease_type="Disease or Syndrome" abbrv="">beta-thalassemia major</z:e> aged from 1.3 to 8.3 years (8 male and 4 female) received UCBT </plain></SENT>
<SENT sid="5" pm="."><plain>Eleven of the twelve donors were siblings and one was unrelative </plain></SENT>
<SENT sid="6" pm="."><plain>Eight patients received no antigen and four patients received two antigen disparate grafts </plain></SENT>
<SENT sid="7" pm="."><plain>According to the Pesaro's classification for <z:e sem="disease" ids="C0039730" disease_type="Disease or Syndrome" abbrv="">thalassemia</z:e>, 10 patients were at grade I or II, and 2 were at grade III </plain></SENT>
<SENT sid="8" pm="."><plain>The HLA-identical patients accepted the conditioning regimen consisting of <z:chebi fb="0" ids="28901">busulfan</z:chebi>, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> and antithymocyteglobulin </plain></SENT>
<SENT sid="9" pm="."><plain>The HLA-mismatched patients accepted the conditioning regimen consisting of hypertransfusions, continuous iv <z:chebi fb="0" ids="4356">desferrioxamine</z:chebi>, <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi>, fludarabine, <z:chebi fb="0" ids="28901">busulfan</z:chebi>, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> and antithymocyteglobulin </plain></SENT>
<SENT sid="10" pm="."><plain>The harvest stem cells contained 3.63 - 16.0 x 10(7)/kg of nucleated cells, 0.11 - 1.03 x 10(6)/kg of CD(34)(+) cells and 0.17 - 1.18 x 10(5)/kg of colony-forming-unit-granulocyte macrophages </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="0" ids="4031">Cyclosporine</z:chebi> alone or in combination with <z:chebi fb="0" ids="168396">mycophenolate</z:chebi> mofetil (MMF) was given for <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (aGVHD) prophylaxis </plain></SENT>
<SENT sid="12" pm="."><plain>RESULTS: Of the 12 patients, 10 were engrafted </plain></SENT>
<SENT sid="13" pm="."><plain>Ten patients had neutrophil recovery (&gt; 0.5 x 10(9)/L) and seven patients had platelet recovery (&gt; 50 x 10(9)/L) </plain></SENT>
<SENT sid="14" pm="."><plain>The median time was 18.1 and 57.3 days, respectively </plain></SENT>
<SENT sid="15" pm="."><plain>Seven patients had disease-free survival (DFS) at a median follow up of 23 months (range 4 - 63 months) </plain></SENT>
<SENT sid="16" pm="."><plain>Three patients had rejection and autologous hematopoitic reconstitution </plain></SENT>
<SENT sid="17" pm="."><plain>Two patients were not engrafted </plain></SENT>
<SENT sid="18" pm="."><plain>One patient acquired severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, another patient died of severe <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> </plain></SENT>
<SENT sid="19" pm="."><plain>The incidences of grade I and grade II aGVHD were 60% (6/10) and 40% (4/10), respectively </plain></SENT>
<SENT sid="20" pm="."><plain>There were no long-term complications in the disease free survivors </plain></SENT>
<SENT sid="21" pm="."><plain>CONCLUSIONS: Grade I-II <z:e sem="disease" ids="C0002875" disease_type="Disease or Syndrome" abbrv="">beta-thalassemia major</z:e> patients receiving sibling UCBT had high DFS </plain></SENT>
<SENT sid="22" pm="."><plain>UCBT is an effective way to treat <z:e sem="disease" ids="C0002875" disease_type="Disease or Syndrome" abbrv="">beta-thalassemia major</z:e> </plain></SENT>
</text></document>